GTHX earnings
G1 Therapeutics Inc. (GTHX) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights- Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenue - - Reaffirmed 2024 Net COSELA Revenue Guidance of Between $60 and $70 Million - - Due to the Pending Transaction with Pharmacosmos, G1 will Not Host a Conference Call and Webcast to Discuss the Second Quarter Financial Results and Business Update - RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today
- Pharmacosmos Group to Acquire G1 Therapeutics- Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos' Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC - - Transaction Expands and Strengthens Pharmacosmos' Global Commercial Portfolio - - G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Million - RESEARCH TRIANGLE PARK, N.C. and HOLBAEK, Denmark, Aug. 07, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASD
- G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar
- G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) Will Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in 1L Metastatic Triple Negative Breast Cancer (mTNBC) Is Expected to Occur in Late Second Quarter of 2024 - - Cash Runway Expected to Extend into the Third Quarter of 2025 - - Management to Host Webcast and Co
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in Metastatic Triple Negative Breast Cancer is Estimated to Occur in the Third Quarter of 2024 - - Presented New Analyses Indicating that Patients Who Previously Received Trilaciclib in a Clinical Trial Setting Experienced Improved Overall Survival with Subsequent Anticancer Therapies - - Provided Initial Results f
- G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The web
- G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter - - Confirmed Expectation of Interim Overall Survival (OS) Analysis for Pivotal Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Reiterated Expectation of Initial OS Results from Phase 2 Trial of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in the First Quarter of 2024 - - COSELA Recommended in Updated American Society of Clinical Oncology (ASCO) Small Cell Lung Cancer (SCLC) Guidelines - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEAR
- G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the compan
- G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New Phase 2 Results Confirming Benefit of Trilaciclib in Reducing Adverse Events Associated with an Antibody-Drug Conjugate (ADC) in Triple Negative Breast Cancer (TNBC) - - Provided Phase 2 Mechanism of Action Trial Results Clarifying Trilaciclib's Role in Enhancing Immune Surveillance and Efficacy as Measured by Long Term Endpoints like Overall Survival (OS) - - Improved Financial Strength By Ame
- G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the com
- G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's
- G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page
- G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through 4 - - However, Early Anti-Tumor Efficacy Data Favored Placebo Arm Over the Trilaciclib Arm - - Despite Achievement of Co-Primary Endpoints, G1 to Terminate PRESERVE 1 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-pr
- G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - - Provided Encouraging Initial Data from Phase 2 Trial Demonstrating Potential of Trilaciclib to Reduce (>50%) the Rates of Adverse Events (AEs) Related to an Antibody-Drug Conjugate (ADC) - - Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer (mTNBC) (PRESERVE 2) - - Completed Patient Enrollment in Phase 2 Clinical Trial of Trilaciclib in Combination with Chemotherapy and Avelumab in Patients with Bladder Cancer (mUC) (PRESERVE 3) - - Announced Acceptance of Abstract of Initial Res
- G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2022 on Wednesday, November 2, 2022, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the co
- G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Colorectal Cancer (mCRC) (PRESERVE 1) - - Completed Patient Enrollment in Phase 2 Mechanism of Action Trial of Trilaciclib in Neoadjuvant Triple Negative Breast Cancer (TNBC) - - Achieved Target Enrollment in Phase 2 Trial of Trilaciclib in Bladder Cancer (mUC) (PRESERVE 3) - - Announced Approval of COSELA (trilaciclib hydrochloride for injection) with Simcere in China - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK
- G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET. Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the com
- G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Fully Deployed G1's COSELA Sales Team as of Mid-February 2022 - - Confirmed Expected Timelines for Initial Results of Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib - - Presented Real-World Data Showing Impact of Trilaciclib on Hospitalizations and Burden of Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Undergoing Chemotherapy - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc.
- G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2022 on Wednesday, May 4, 2022 at 8:30 a.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 2229795. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization
- G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights- Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Completed Hiring, Training, and Deployment of G1's COSELA Sales Team - - Announced That Initial Results from Phase 3 Trial of Trilaciclib in Colorectal Cancer (PRESERVE 1) Are Now Expected Early in the First Quarter of 2023 - - Initiated Two New Phase 2 Trials to Confirm the Immune-Based Mechanism of Action (MOA) of Trilaciclib and to Help Clarify the Potential Synergistic Effects of Trilaciclib and an Antibody-Drug Conjugate (ADC) - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Feb.
- G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 5256086. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and
- G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34. The expansion will allow G1 to target all accounts to accelerate sales activities and help maximize the adoption of COSELA™ (trilaciclib). G1 and Boehringer Ingelheim have mutually agreed to end the co-promotion agreement for COSELA, effective March 2022. "W
- G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights- Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA - - Initiation of Two New Phase 2 Trials Expected in the Fourth Quarter of 2021 to Further Investigate Trilaciclib's Immune-Based Mechanism of Action (MOA) and Potential Benefits in Combination with an Antibody-Drug Conjugate (ADC) - - Amended Debt Facility Extends Cash Runway into 2024 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:
- G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercializa
- G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights- Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer (TNBC) Evaluating the Survival Benefit of COSELA Compared with Placebo - - Initiated Randomized Phase 2 Studies of COSELA in Non-Small Cell Lung Cancer (NSCLC) and Bladder Cancer - - Received Fast Track Designation from U.S. Food and Drug Administration (FDA) for COSELA in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic TNBC - - Management to Host Webcast and Conference Call today at 4:30 PM ET - RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) --
- G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 3553037. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercializat